About our Company

Our Mission

  • Impeto Medical is a privately owned medical device company created in June 2005. Its corporate headquarters are located in Paris, France. The company is also present in San Diego, CA, USA.

  • Our goal is to provide the medical community with screening tests to face epidemically spreading metabolic disorders and their complications.
  • By providing less invasive, faster and less costly procedures, we enable physicians to screen larger patient populations and to detect diseases complications earlier.
  • We build value for our investors through constant innovation based on clinical research as well as focus on priority medical issues.


The SUDOCAN® device is covered by the following patents and designs:

  • “Electrophysiological analysis system and method” (US Patent No. US 8965497B2, European Patent
    No. EP 1898783B1),

  • “Electrophysiological analysis system”
    (US Patent No. US 8655443B2, European Patent
    No. EP 2124736B1),

  • “Assessment of sudomotor function for peripheral diabetic neuropathy evaluation” (US Patent No. US 8934954B2),

  • “Device for measuring electrophysiological data with impoved reliability” (US Patent No. US 10537272B2),

  • “Electrodes” (US Designs No. D815746 and D796681, European Designs
    No. EU0028464100001S and EU0028464100002S)

Certification System
ISO 13485:2016

Impeto Medical SAS

2 rue Maurice Hartmann, 92130 Issy Les Moulineaux
Tel: +33 (0)7 87 20 32 03
Email: info@impeto-medical.com

The advantage of
Neuropathy Early Detection

An innovative device for early detection and follow-up
of Autonomic and Small Fiber Neuropathy.

Simple results obtained in 3 minutes.